![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 24, 21984-21989, June 15, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the We have shown previously that serum promotes T
cell proliferation by acting with T cell receptor (TCR) agonists to
efficiently down-regulate p27Kip1 and activate
cdk2-containing complexes. In the studies described here, the effect of
serum on the expression of the
Interdependence of cdk2 Activation and Interleukin-2R
Accumulation in T Cells*
§ and
§¶
Molecular Oncology Program, H. Lee Moffitt
Cancer Center and Research Institute, § Department of
Oncology, and Department of Biochemistry and Molecular Biology,
University of South Florida College of Medicine, Tampa, Florida
33612
subunit of the interleukin-2
receptor (IL-2R
) was examined. We found that serum was required for
maximal and sustained IL-2R
protein expression and consequent IL-2
signaling in TCR-activated splenocytes. Serum had no effect on IL-2R
mRNA levels and thus modulates IL-2R
expression
post-transcriptionally. Unlike wild-type splenocytes, splenocytes
exhibiting serum-independent cdk2 activation due to loss of
p27Kip1 efficiently expressed IL-2R
in serum-deficient
medium. Conversely, serum did not promote IL-2R
accumulation in
conditions in which cdk2 activity was blocked. These findings
demonstrate that cdk2 activation is necessary and sufficient for
IL-2R
accumulation in TCR-stimulated splenocytes. On the other hand,
IL-2 signaling was required (at least in part) for cdk2 activation in
these cells. Thus, cdk2 activation, IL-2R
expression, and IL-2
signaling are interdependent events, and we suggest that this
feed-forward regulatory loop plays a key role in T cell mitogenesis.
*
This work was supported by the Cortner-Couch Endowed Chair
for Cancer Research and National Institutes of Health Grants CA72694 and CA67360.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article has been cited by other articles:
![]() |
L. A. Wolfraim, T. M. Walz, Z. James, T. Fernandez, and J. J. Letterio p21Cip1 and p27Kip1 Act in Synergy to Alter the Sensitivity of Naive T Cells to TGF-{beta}-Mediated G1 Arrest through Modulation of IL-2 Responsiveness J. Immunol., September 1, 2004; 173(5): 3093 - 3102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mohapatra, B. Chu, S. Wei, J. Djeu, P. K. Epling-Burnette, T. Loughran, R. Jove, and W. J. Pledger Roscovitine Inhibits STAT5 Activity and Induces Apoptosis in the Human Leukemia Virus Type 1-Transformed Cell Line MT-2 Cancer Res., December 1, 2003; 63(23): 8523 - 8530. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Olashaw and W. J. Pledger Paradigms of Growth Control: Relation to Cdk Activation Sci. Signal., May 28, 2002; 2002(134): re7 - re7. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mohapatra, D. Agrawal, and W. J. Pledger p27Kip1 Regulates T Cell Proliferation J. Biol. Chem., June 8, 2001; 276(24): 21976 - 21983. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |